China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
Inc. (the “Company”) (Nasdaq: CMED), a leading
diagnostic (“IVD”) company, today announced that its HER-2 FISH probe has been
chosen to be used in a research project focusing on cancer targeted therapy
standardization, as well as early cancer detection and treatment, which is
sponsored by the Chinese Ministry of Health. One of the subjects of this
research project is to standardize the process and procedures for the use of
FISH technology to detect HER-2 gene amplification in breast cancer and
stomach cancer patients to guide the use of Herceptin (the “HER-2 Study”). The
Company is the supplier of HER-2 FISH probe for the HER-2 Study.
Immunohistochemistry used to be the traditional diagnostic method in
detecting HER-2 gene amplification in
false negative results. The HER-2 Study is the first study in
FISH technology as the gold standard in HER-2 gene amplification detection.
The Company believes that the results of the HER-2 Study may contribute to
more widespread use of its HER-2 FISH probe in the companion diagnostic test
According to the Chinese Central Government’s Official Web Portal, about
200,000 new cases of breast cancer and 400,000 new cases of stomach cancer are
“We believe that our selection as the supplier of HER-2 FISH probe in the
HER-2 Study by the top ranking cancer research institute demonstrates the good
quality of our HER-2 FISH probe,” commented Mr.
Chief Executive Officer of the Company.
The HER-2 Study is led by the Cancer Institute and Hospital of the Chinese
Academy of Medical Sciences with Dr.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading
company using molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an
immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA),
to develop, manufacture and distribute diagnostic products used for the
detection of various cancers, diseases and disorders as well as companion
diagnostic tests for targeted cancer drugs. The Company generates all of its
probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are
recurring users of the consumables for their patients. The Company sells FISH
probes and SPR chips to large hospitals through its direct sales force and
ECLIA reagent kits to small and mid-size hospitals through distributors. For
more information, please visit http://www.chinameditech.com .
Safe Harbor Statement
This press release contains forward-looking statements. These statements
constitute “forward-looking” statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as “will,” “expects,”
“anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and
similar statements. Such statements involve certain risks and uncertainties
that could cause actual results to differ materially from those in the
forward-looking statements, including the risk that the results of the HER-2
Study will not lead to increased use of the Company’s HER-2 FISH probe.
Further information regarding these and other risks is included in the
Company’s filings with the U.S. Securities and Exchange Commission, including
its annual report on Form 20-F. The Company does not undertake any obligation
to update any forward-looking statement as a result of new information, future
events or otherwise, except as required under applicable law.
For more information, please contact: Winnie Yam Phone: +852-2511-9808 Email: IR@chinameditech.com
SOURCE China Medical Technologies, Inc.